title: The effect of poly (aspartic acid-co-lactic acid) nanospheres on the lung metastasis of B16BL6 melanoma cells by intravenous administration.
abstract: Poly (aspartic acid-co-lactic acid) (PAL) has been investigated as a new biodegradable material for Drug Delivery Systems (DDS). Similar to the poly (lactic acid-co-glycolic acid) (PLGA) nanospheres, the PAL nanospheres can control-release encapsulated drugs by hydrolysis and adhere to the mucous membranes to improve the drug absorption. In this study, the vitamin encapsulated PAL nanospheres were applied on mice to examine their effect on tumor metastasis and safety as an injectable DDS material for anti-cancer and other drugs. In the experiment, 6 C57BL/6 mice per group were intravenously administered with B16BL6 melanoma cells (1 x 10(5) per mouse) and non-encapsulated PAL nanospheres or pro-vitamin encapsulated nanospheres respectively, while the control group was administered with B16BL6 cells alone. Two weeks later, the lungs of the mice were excised and metastatic foci on the lung surface were counted. The melanoma cell metastasis to lungs was prevented by intravenous co-injection of B16BL6 melanoma cells with 1.7 microg of pro-vitamin E encapsulated PAL nanospheres. Its metastatic foci count (mean +/- SD) was 127+/-80, which was better than the control (246+/-95, p<0.02). Also, applying the pro-vitamin C and pro-vitamin A encapsulated PAL nanospheres as well as the non-encapsulated PAL nanospheres slightly decreased the number of metastasis colonies in the lungs as compared to that of the control. These results suggested that PAL nanospheres did not promote the lung metastasis of B16BL6 melanoma cells. Thus, the PAL nanospheres are safe material for injection applications.
authors.affiliation: Hosokawa Powder Technology Research Institute, Tajika, Hirakata, Osaka 573-1132, Japan. khara@hmc.hosokawa.com
authors.forename: Kaori
authors.initials: K
authors.lastname: Hara
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tsujimoto
authors.forename: C C
authors.initials: CC
authors.lastname: Huang
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kawashima
authors.forename: Haruko
authors.initials: H
authors.lastname: Mimura
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Miwa
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000008:administration & dosage*; D045744:Cell Line, Tumor; D003692:Delayed-Action Preparations; D007275:Injections, Intravenous; D019344:Lactic Acid / Q000008:administration & dosage; D008175:Lung Neoplasms / Q000517:prevention & control* / Q000556:secondary; D008545:Melanoma / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D053769:Nanocapsules; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009368:Neoplasm Transplantation; D010455:Peptides / Q000008:administration & dosage; D011355:Prodrugs / Q000008:administration & dosage; D014815:Vitamins / Q000008:administration & dosage*
chemical_list: D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D053769:Nanocapsules; D010455:Peptides; D011355:Prodrugs; D014815:Vitamins; C017645:polyaspartate; D019344:Lactic Acid